Alumis posts envudeucitinib LUMUS Phase 2b topline results presentation
ALMS•Subgroup efficacy and safety
The prespecified IFNGS-high subgroup showed stronger outcomes, with BICLA response reaching 52.6% on 40 mg BID versus 28.6% for placebo.
The safety profile appeared favorable, with no new safety signals reported and lower adverse-event rates on active treatment versus placebo.
LUMUS Phase 2b topline results
Alumis released topline results from the LUMUS Phase 2b trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus.
The study missed its primary endpoint of BICLA response at week 48 across the overall population, with placebo response elevated. Placebo BICLA response was 35.7% versus 40%–42.2% for envudeucitinib, and p-values ranged from 0.35 to 0.5.
